Experimental heart medication fails to reduce cardiovascular events in trial

A promising cardiovascular medication failed to lower heart attack and stroke rates in clinical testing.

Medical researchers suffered a setback after a heavily anticipated lipid-lowering medication proved ineffective at preventing heart attacks and strokes. Full trial data showed the compound performed no better than a placebo in protecting patients. Specialists are now questioning underlying assumptions about treating cardiovascular disease.

• The findingsFull trial data revealed the treatment offered no advantage over dummy pills.
• The outlookPhysicians are re-evaluating long-held theories regarding cholesterol management and cardiac health.

Written from 2 of 4 outlets — 2 have since joined this story.